CDI, the result of intensive efforts and advances developed by the High-Throughput Biology Center at Johns Hopkins University, is a privately owned research and discovery company in the field of proteomics.
The company was created by scientists for scientists, addressing the critical needs required in order to accelerate research, advance discoveries and translate these discoveries into novel products and services that improve human health.
The company applies its accelerating platforms to internal, collaborative, and client programs.
Service and technology dissemination provide immediate revenue.
Internal programs create a pipeline of proprietary biomarker panels and soon-to-be diagnostic and predictive tools in the fields of autoimmunity, oncology, therapeutic outcome and toxicity prediction.
The HuProt™ Human Proteome Microarray contains the worlds largest number of unique, individually-purified human proteins. That’s more than double the not-so-close second.
The comprehensive content of the HuProt™ microarray allows thousands of interactions to be profiled in high-throughput:
-Small Molecule Binding
-Enzyme Substrate ID
The HuProt™ v3.0 Human Proteome Protein Microarray contains >19,000 unique, newly resequenced and individually purified human proteins encompassing >15,000 genes (~75% of the human proteome) and 124 unique mouse gene symbols. Recombinant proteins are expressed in yeast (S. cerevisiae), purified and printed on nitrocellulose-coated glass slides in duplicate, along with control proteins.
CDI now uses the Arrayjet Ultra Marathon II non-contact piezoelectric (inkjet) printer for the manufacture of all microarrays with significant performance advantages over contact print methods:
• precise spot morphology
• reduced inter- and intra-array variability
• greater data reproducibility
• large batch sizes for large cohort analysis
• rapid production of custom configured arrays
Circulating disease related autoantibodies - or disease biomarkers are invaluable for screening patients for pathologies such as cancer, autoimmune disorders, infectious diseases and also to monitor the effectiveness of subsequent treatments.
The CDI HuProt microarray contains nearly 75% of the human proteome on a single glass slide, a unique and powerful tool for high-throughput serum profiling and biomarker discovery.
In addition to analysis using the full HuProt microarray, CDI can custom print microarrays containing up to 14 separate subarrays -each containing only proteins of interest as determined during the discovery phase. In this configuration, 14 individual samples can be run on a single microarray - a substantial cost savings.
HuProt Microarray Characteristics
Fast-MAb is CDI's microarray-powered custom monoclonal antibody development and specificity validation service with access to -20,000 antigens.
Fast-MAb addresses the urgent need for monoclonal antibodies with unprecedented specificity to native human proteins with delivery in 8 weeks.
CDI utilizes its HuProt™ Human Proteome Microarray for validating the final product – therefore your antibody will be screened for cross-reactivity against thousands of human proteins - - 75% of the human proteome.
Be Specific. Whether you are grant-writing, publishing or manufacturing... make CDI Fast-MAb part of your discovery and development success.
Antibody Cross-Reactivity Testing
CDI will specificity-test your antibody against over 19,000 human recombinant proteins - native & denatured - and at 2 working concentrations.
High-Spec Cross-Reactivity Testing leverages the power of the HuProt™ microarray to help pharmaceutical companies assess their therapeutic antibody pipeline quickly and cost-effectively, thus increasing the number of new treatments discovered, and identifying losers earlier.
Research reagent companies developing commercial antibodies can realize a tremendous quality advantage by offering products with unmatched levels of specificity that can bolster academic research programs at all stages – from grant application to publication. Be Specific.
CDI NextGen Proteomics has not received any reviews.
CDI NextGen Proteomics has not received any endorsements.